As shown in Table 1, HHV-8 seroprevalence was higher among men with prostate cancer (11%) when compared to the control group (6%; unadjusted OR 1.75; 95% CI: 1.23–2.46) and remained significantly elevated among cases in the confounder-adjusted logistic regression analysis that included IFNL4 rs368234815 (ΔG/ΔG or ΔG/TT vs. TT/TT) as covariate (adjusted OR 1.76; 95% CI: 1.20–2.59; Table 2). Here, IFNL4 is linked to prostate carcinoma.